AACR San Diego 2026: New Drugs on the Horizon

Key Takeaways

• NEO‑811 degrades HIF‑1β/ARNT for VHL‑deficient renal cancer
• AZD8359 STEAP2 T‑cell engager cuts cytokine release
• CRBN glues TNG961 and TRI‑611 target undruggable proteins
• New ADCs CD30 dpADC and JNJ‑89862175 aim to bypass resistance
• ECI830 selective CDK2 inhibitor synergizes with CDK4/6 blockers

Pulse Analysis

The AACR 2026 "Drugs on the Horizon" series underscored a shift toward precision‑engineered modalities that go beyond traditional inhibition. Molecular glues such as NEO‑811, TNG961 and TRI‑611 exploit the CRBN E3 ligase to flag disease‑relevant proteins for degradation, a strategy that promises to tackle resistance pathways that have limited the impact of earlier small‑molecule inhibitors. By designing neo‑degrons that avoid off‑target neosubstrate degradation, these agents aim for higher therapeutic windows, positioning them as attractive assets for both biotech innovators and large pharma partners seeking differentiated pipelines.

Equally notable is the emergence of next‑generation immunotherapies. AZD8359 leverages a 2+1 antibody format to engage CD8⁺ T cells against STEAP2‑positive prostate tumors while dampening cytokine release, addressing safety concerns that have hampered earlier T‑cell engagers. Parallel advances in bispecific and ADC platforms—exemplified by EPI‑326’s EGFR‑directed bispecific, CD30 dpADC’s dual‑payload design, and JNJ‑89862175’s ENPP3‑targeted ADC—illustrate a concerted effort to overcome antigen escape and drug resistance in hematologic and solid tumors. These constructs combine novel payloads, linker chemistries, and targeting strategies to broaden the therapeutic index.

From a market perspective, the pipeline influx signals heightened competition and potential partnership opportunities. Early‑stage candidates like ECI830, a highly selective oral CDK2 inhibitor, demonstrate synergistic activity with existing CDK4/6 inhibitors, hinting at combination regimens that could extend the lifespan of current standards of care. Meanwhile, companies such as Amphista and Circle Pharma are advancing degraders and macrocycles into Phase 1 trials, reflecting investor confidence in unconventional mechanisms. As these agents progress, investors and clinicians will watch closely for clinical readouts that could redefine treatment algorithms across renal, prostate, lung, breast and lymphoma indications.